Dyspepsia future or investigational therapies
|
Dyspepsia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dyspepsia future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Dyspepsia future or investigational therapies |
|
Risk calculators and risk factors for Dyspepsia future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future or Investigational Therapies
A 2004 meta-analysis pooling data from three double-blind placebo-controlled studies found the multiple herbal extract Iberogast to be significantly more effective than placebo (p value = 0.001) at treating patients with functional dyspepsia through the targeting of multiple dyspeptic pathologies[1]. This German-made phytopharmaceutical was found to be equivalent to cisapride and significantly superior to metochlopramide at reducing the symptoms of functional dyspepsia over a four week period.[2][3] Retrospective surveillance of 40,961 children (12 years and under) found no serious side-effects[4].
References
- ↑ Melzer J, Rosch W, Reichling J, Brignoli R, Saller R (2004). "Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW-5 (Iberogast)". Aliment Pharmacol Ther. 20: 1279&ndash, 87.
- ↑ Rosch w, Vinson B, Sassin, I (2002). "A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia". Z Gastroenterol. 40: 401&ndash, 8.
- ↑ Hanisch J, Bock P, Vinson B (2005). "The efficacy and safety of STW 5 versus Metochlopramide oral for functional dyspepsia under practice conditions (in German)". Med Klinik. 100. Text "pages107" ignored (help)
- ↑ Liechtle K (1999). "Experience reports on the use of Iberogast in children (in German)". Forschungsbericht Steigerwald Arzneimittelwerk. GmbH.